Tech Company Financing Transactions
Centrexion Therapeutics Funding Round
New Enterprise Associates, ArrowMark Partners and Quan Capital participated in a $67 million Series D funding round for Centrexion Therapeutics. This venture round closed on 1/3/2018.
Transaction Overview
Company Name
Announced On
1/3/2018
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds will be used to fund the Phase 3 program for Centrexion's lead therapy, CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic pain due to knee osteoarthritis (OA). CNTX-4975 is a highly differentiated, novel, non-opioid therapy that is designed to be injected directly into the painful joint.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 State St.
Boston, MA 02109
USA
Boston, MA 02109
USA
Phone
Website
Email Address
Overview
We are advancing a valuable, unique and diversified pipeline of non-opioid treatments for chronic pain through internal development and strategic in-licensing. Using insights into the biology of pain and the knowledge mined from big data and translational science, we are focused on transforming pain management with real innovation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sol Barer
Chief Executive Officer
Jeffrey Kindler
Chief Medical Officer
Randall Stevens
Chief Scientific Officer
James Campbell
VP - Bus. Development
Kerrie Brady
Browse more venture capital transactions:
Prev: 1/3/2018: Avitide venture capital transaction
Next: 1/3/2018: Breethe venture capital transaction
Share this article
News on VC Transactions
We do our best to record funding rounds that are announced publicly. VC transactions on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs